Skip to content →

Clay Siegall’s Impeccable Leadership Soars Seattle Genetics Higher in the Field of Oncology

 

Clay B. Siegall is a distinguished scientist who mainly focuses on cancer therapies. He is a co-founder of a leading research and drug development company dubbed Seattle Genetics. He is the chair of the firm’s board and CEO. Under his keen eye, the company has grown to develop antibody-drug conjugates such as ADCETRIS successfully. He also led the company in getting 2011 FDA approval for the drug, which has become a known brand in over 65 countries across the globe.

 

Leadership Prowess

 

Clay Siegall has successfully negotiated profit making partnerships for Seattle Genetics’ antibody-drug conjugates with big firms, such as GlaxoSmithKline, Genentech (Roche), AbbVie, and Pfizer. His efforts have fetched more than 350 million dollars for Seattle Genetics and have seen many clinical firms adopt the Seattle Genetics technology. This strategy has allowed Seattle Genetics to use their resources to new ideas and methods to the benefit of patients. Siegall also led the company’s initial public offer in 2001, and he has sourced for funding of up to $1.2 billion privately and publicly.

 

His Driving Force

 

According to Clay Siegall, his desire to improve the field of oncology is what drove him to Seattle Genetics. The realization that the area was marked with poor tools came when his father was ailing with cancer in his early life. Since then, he has been dedicated to making a difference in this field. Treating cancer patients and eventually doing better continually is Siegall’s ultimate goal. Over the years, Siegall has surrounded himself with smart people who have helped him learn a lot in business and oncology. A trait he would recommend to any entrepreneur.

 

About Clay Siegall

 

Clay Siegall background training is in genetics to a Ph.D. level and zoology at degree level. This set him to start and uphold a career in oncology successfully. Before co-founding Seattle Genetics, Siegall worked at the Bristol-Myers. He also held senior positions at National Cancer Institute. He serves on the Directors Board for several institutions, including Alder Biopharmaceuticals, Washington Roundtable, and Ultragenyx Pharmaceuticals. Siegall’s efforts have seen him win the prestigious Young CEO of the Year back in 2012 among other recognitions.

Published in Cancer Research

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *